Study explores incidence, severity, and long COVID associations of SARS-CoV-2 reinfections medrxivpreprint RTI_Intl COVID19 SARSCoV2 LongCOVID COVIDReinfection Severity
By Dr. Chinta SidharthanJan 10 2023Reviewed by Aimee Molineux In a recent study posted to the medRxiv* preprint server, a team of researchers from the United States used electronic health records to characterize the incidence, biomarkers, attributes, and severity of severe acute respiratory syndrome coronavirus 2 reinfections and evaluated the association between reinfections and long coronavirus disease .
Reinfection was defined based on a positive SARS-CoV-2 antigen or polymerase chain reaction test more than 60 days after the index date for the initial SARS-CoV-2 infection. Long COVID was defined based on the International Classification of Diseases, Tenth Revision, Clinical Modification codes. Immunology eBook Compilation of the top interviews, articles, and news in the last year. Download a free copy COVID-associated hospitalization data was used to determine the severity of reinfections.
Analyses of biomarkers revealed that compared to the initial SARS-CoV-2 infection, reinfections showed lower elevation of hepatic inflammation markers such as alanine transaminase and aspartate transaminase . However, albumin levels were consistently low in reinfection patients.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Researchers study the spatial distribution of SARS-CoV-2 Omicron BA.1 variant in EnglandResearchers performed a genomic assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant’s BA.1 subvariant transmission in England.
Read more »
New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systemsIn a recent study posted to the bioRxiv* preprint server, researchers at Emory University used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Washington (WA.1) and Omicron (BA.1) strains to test for mutations that could result in resistance to the antiviral drug nirmatrelvir.
Read more »
Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine dosesIn a recent correspondence published in The Lancet Infectious Diseases journal, researchers in Germany assessed the neutralization sensitivity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB.1 lineage.
Read more »
Frontiers | Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19Background: Gastrointestinal disorders are frequent in COVID-19 and SARS-CoV-2 has been hypothesized to impact on host microbial flora and gut inflammation, infecting intestinal epithelial cells. Since there are currently no coded therapies or guidelines for treatment of COVID-19, this study aimed to evaluate the possible role of a specific oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Methods: We provide a report of 70 patients positive for COVID-19, hospitalized between March 9th and April 4th, 2020. All the patients had fever, required non-invasive oxygen therapy and presented a CT lung involvement on imaging more than 50%. Forty-two patients received hydroxychloroquine, antibiotics, and tocilizumab, alone or in combination. A second group of 28 subjects received the same therapy added with oral bacteriotherapy, using a specialized formulation of eight bacterial strains. Results: The two cohorts of patients were comparable for age, sex, laboratory values, concomitant pathologies, and the modality of oxygen support. Within seventy-two hours, nearly all patients treated with bacteriotherapy showed remission of diarrhea and other symptoms as compared to less than half of the not supplemented group. The estimated risk of developing respiratory failure was eight-fold lower in patients receiving oral bacteriotherapy. Both the prevalence of patients transferred to ICU and mortality were higher among the patients not treated with oral bacteriotherapy. Conclusions: A specific bacterial formulation showed a significant ameliorating impact on the clinical conditions of patients positive for SARS-CoV-2 infection. These results also stress the importance of the gut-lung axis in controlling the COVID-19 disease.
Read more »
Is universal coronavirus immunity possible?In a recent study posted to the bioRxiv* preprint server, researchers at Columbia University characterized reciprocal and non-reciprocal T-cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Read more »
Incidence rates and characteristics associated with medically attended COVID-19 episodes among infants younger than 6 monthsIncidence rates and characteristics associated with medically attended COVID-19 episodes among infants younger than 6 months PIDJournal bcmhouston aboutKP COVID19 coornavirus covid infants
Read more »